Legend Biotech (LEGN) Total Non-Current Liabilities (2019 - 2024)
Legend Biotech (LEGN) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $352.0 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Total Non-Current Liabilities fell 7.58% year-over-year to $352.0 million, compared with a TTM value of $352.0 million through Dec 2024, down 7.58%, and an annual FY2024 reading of $352.0 million, down 7.58% over the prior year.
- Total Non-Current Liabilities was $352.0 million for Q4 2024 at Legend Biotech, down from $380.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $380.8 million in Q4 2023 and bottomed at $8.8 million in Q4 2020.
- Average Total Non-Current Liabilities over 5 years is $230.9 million, with a median of $288.9 million recorded in 2022.
- The sharpest move saw Total Non-Current Liabilities tumbled 96.9% in 2020, then surged 1319.95% in 2021.
- Year by year, Total Non-Current Liabilities stood at $8.8 million in 2020, then soared by 1319.95% to $124.3 million in 2021, then skyrocketed by 132.36% to $288.9 million in 2022, then surged by 31.83% to $380.8 million in 2023, then fell by 7.58% to $352.0 million in 2024.
- Business Quant data shows Total Non-Current Liabilities for LEGN at $352.0 million in Q4 2024, $380.8 million in Q4 2023, and $288.9 million in Q4 2022.